
- Orion’s second-quarter net sales reached EUR 416.5 million, surpassing expectations of EUR 380.4 million.
- The company’s EBIT stood at EUR 104.6 million, with an EBIT margin of 25.1%.
- Pretax profit came in at EUR 103.4 million, exceeding the estimate of EUR 94.9 million.
- Orion upgraded its 2025 outlook in July, projecting net sales between EUR 1,630 million and EUR 1,730 million.
- This upgraded outlook assumes a significant increase in Nubeqa® royalties and product sales in 2025.
- Capital expenditure in 2025 is expected to remain similar to 2024 levels.
- The rise in operating profit was fueled by increased Nubeqa® royalties.
- Branded Products and Animal Health divisions saw growth driven by a diverse product portfolio.
- Orion’s shares rose by 2.7% to EUR 67.85, with 55,422 shares traded.
- Analysts’ recommendations include 5 buy ratings, 1 hold, and 2 sells.
A look at Orion Oyj Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 2 | |
Dividend | 3 | |
Growth | 4 | |
Resilience | 4 | |
Momentum | 5 | |
OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Orion Oyj, a company specializing in pharmaceuticals and diagnostic kits, demonstrates a promising long-term outlook according to the Smartkarma Smart Scores. With a strong momentum score of 5, Orion Oyj is showing significant positive movement in the market. This indicates that the company is gaining traction and investor interest, which may lead to potential future growth opportunities.
Furthermore, Orion Oyj scores well in growth and resilience with scores of 4, suggesting that the company has solid potential for expanding its operations and is well-equipped to withstand economic uncertainties or challenges. Additionally, the company scores a respectable 3 in dividends, indicating a decent return for investors. However, the value score of 2 implies that the company may be slightly undervalued, presenting a potential opportunity for growth in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars